References

1 Le médecin fournissait trop de cobayes, France - Soir, (daily newspaper), Friday 15 December 2000.

2 European Parliament and Council Directive, 2001/20/EC, relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.

3 Note for guidance on good clinical practice (CPMP/ICH/135/95).

4 Lock SP, Wells FO eds. Fraud and Misconduct in Medical Research, Second edition London: BMJ Publishing Group, 1996.

5 Association of the British Pharmaceutical Industry. Statistical methods in the investigation of fraud London: ABPI, 1993.

6 Buyse M, George SL, Evans S et al. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Control Clin Trials 2000;21:415-27.

7 Recommandations du groupe de travailde la Mission de réflexion sur l'intégrité scientifique, actualités, bulletin de l'institut national de la santé et de la recherche médicale, 1998,162:6-9.

8 Chuat JC. INSERM, délégation à l'intégrité scientifique, personal communication.

9 Bungener M. Procedures for inquiring into Allegations of Scientific Misconduct at INSERM. In: Plehn G, ed. Ethics of Research, Max Planck Forum 2, Munich: Max Planck Publishers, 1999.

10 Le Monde (daily newspaper) 3 articles on a Rennes INSERM unit. Le Hir P, Le géne de l'obésité à l'épreuve du soupçon, 22 April 1988.

Brun J-P, Lenfant J, Pourquoi taire unr fraude scientifique? 18 July 1998. Augereau J-F, L'unité de Rennes sur l'obésité fermée par l'INSERM 29 July 1998.

11 Leech DH. Guaranteeing Good Science Practice in the UK. In: Plehn G, ed. Max Planck Fourm 2. Munich: Max Planck Publishers, 1999.

12 Husson JM, Bogaievsky Y, Hvidberg E, Schwarz J, Chadha D, Fraud in clinical research on medicines in the European Union: facts and proposals. In: Lock SP, Wells FO, eds, Fraud and Misconduct in Medical Research, second edition. London: BMJ Publishing Group, 1996.

13 Berthoye PH. Eléments pouvant motiver une inspection, Eléments pouvant invalider un essai clinique Meeting on Intégrité et authenticité des données dans la recherche clinique: buts, moyens et conséquences des inspections des essais cliniques, Paris, 20 January 2000.

14 Berthoye PH.: personal communication on Afssaps inspêction figures, with the authorisation of Afssaps.

15 Smith R. The need for a national body for research misconduct. Nothing less will reassure the public, Editorial. BMJ, 1998;316:1686-7.

16 Riis P. Misconduct in clinical research: The Scandinavian experience and actions for prevention. Acta Oncologica, 1999;38:89-92.

Was this article helpful?

0 0

Post a comment